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Abstract
Background: Electrotransfer of plasmid DNA into skeletal muscle is a promising strategy for the delivery of therapeutic
molecules targeting various muscular diseases, cancer and lower-limb ischemia. Internal Ribosome Entry Sites (IRESs)
allow co-expression of proteins of interest from a single transcriptional unit. IRESs are RNA elements that have been
found in viral RNAs as well as a variety of cellular mRNAs with long 5' untranslated regions. While the
encephalomyocarditis virus (EMCV) IRES is often used in expression vectors, we have shown that the FGF-1 IRES is
equally active to drive short term transgene expression in mouse muscle. To compare the ability of the FGF-1 IRES to
drive long term expression against the EMCV and FGF-2 IRESs, we performed analyses of expression kinetics using
bicistronic vectors that express the bioluminescent renilla and firefly luciferase reporter genes. Long term expression of
bicistronic vectors was also compared to that of monocistronic vectors. Bioluminescence was quantified ex vivo using a
luminometer and in vivo using a CCD camera that monitors luminescence within live animals.
Results: Our data demonstrate that the efficiency of the FGF-1 IRES is comparable to that of the EMCV IRES for long
term expression of bicistronic transgenes in mouse muscle, whereas the FGF-2 IRES has a very poor activity.
Interestingly, we show that despite the global decrease of vector expression over time, the ratio of firefly to renilla
luciferase remains stable with bicistronic vectors containing the FGF-1 or FGF-2 IRES and is slightly affected with the
EMCV IRES, whereas it is clearly unstable for mixed monocistronic vectors. In addition, long term expression more
drastically decreases with monocistronic vectors, and is different for single or mixed vector injection.
Conclusion: These data validate the use of bicistronic vectors rather than mixed monocistronic vectors for long term
expression, and support the use of the FGF-1 IRES. The use of a cellular IRES over one of viral origin is of particular
interest in the goal of eliminating viral sequences from transgenic vectors. In addition, the FGF-1 IRES, compared to the
EMCV IRES, has a more stable activity, is shorter in length and more flexible in terms of downstream cloning of second
cistrons. Finally, the FGF-1 IRES is very attractive to develop multicistronic expression cassettes for gene transfer in
mouse muscle.
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Background
Gene delivery to skeletal muscle is a promising strategy for
the treatment of muscle disorders such as myopathies
[1,2]. Furthermore, molecules containing secretion
sequences can be expressed in muscle tissue and targeted
to pathologies residing in other organs. Muscle is a highly
vascularized tissue, often regarded as serving endocrine
functions. By expressing therapeutic concentrations of
secreted proteins, such as angiogenic and neurotrophic
factors, in the muscle, a number of therapeutic applica-
tions can be envisioned. Skeletal muscle has been used for
the production of IL-10 in gene therapy against athero-
sclerosis, coagulation factors against haemophilia, eryth-
ropoietin against anaemia and influenza protein for
vaccination [3-6]. Electrotransfer of alpha-2 laminin into
dystrophic mouse muscle successfully produced laminin
around the sarcolemmal membrane without extended
muscle damage [7]. Recently, gene therapy against Duch-
enne muscular dystrophy was shown to be enhanced by
the combined delivery of IGF-1 along with microdys-
trophin [8]. Such combinatorial delivery strategies will
depend upon the development of optimized cassettes
designed to co-express multiple transgenes.
While electrotransfer of plasmid DNA produces less pro-
tein as compared with viral vectors, there remain several
advantages such as reduced toxicity, increased safety, and
easier/cheaper production methods [9,10]. Electrotransfer
of DNA into mouse muscle for gene therapy applications
benefits from additional advantages such as tissue accessi-
bility, efficiency of DNA uptake and long term transgene
expression [11,12].
Internal Ribosome Entry Sites (IRESs) enable vectors to
produce multiple products from a single transcriptional
unit, eliminating the loss of gene expression due to pro-
moter competition or counter-selection [13]. IRESs, RNA
elements that permit cap-independent translation, were
first discovered in viral RNAs but have also been found in
several cellular mRNAs mostly encoding control proteins
such as transcription factors, growth factors or proteins
involved in apoptosis [14-16]. Previous work in our labo-
ratory has shown that cellular IRESs are highly regulated
in vivo and possess tissue specific activities [17-19]. IRESs
are of particular interest for gene therapy since they could
be used to co-express multiple proteins from a single
mRNA [13,20-22].
Non invasive real-time analysis of molecular events in
intact living animals is crucial for many applications such
as gene therapy studies [23-25]. Bioluminescence quanti-
fication and imaging exploit the emission of visible pho-
tons generated by energy-dependent luciferase catalysed
reactions. Firefly luciferase (LucF) converts luciferin to
oxylucyferin, through an ATP-dependent hydrolysis,
which emits photons detected and quantitated with low-
light, charge-coupled device (CCD) cameras. Such cam-
eras can be cooled to -80°C or -120°C to reduce thermal
noise and increase their sensitivity [26]. Applications
developed with these technologies are capable of non-
invasively monitoring luciferase expression in living
mouse muscle [11,27].
Due to alternative transcription initiations, the FGF-1
mRNAs possess 4 different 5'UTRs, three of which contain
IRESs [28]. Compared to other cellular IRESs, the FGF-1
IRES A (referred to as FGF-1 IRES in the text) has a strong
activity in mouse muscle. To investigate the efficiency and
the stability of this IRES as a tool to drive long term trans-
gene expression in mouse muscle, we used the "Lucky
Luke" bicistronic vector, previously validated in cell cul-
ture [28]. A Lucky Luke bicistronic vector containing the
FGF-1 IRES was compared to bicistronic vectors contain-
ing either the EMCV or FGF-2 IRES for expression time
courses extending up to 30 days. Expression of the bicis-
tronic vector bearing the FGF-1 IRES was also compared to
that of monocistronic vectors coding for LucR or LucF,
injected alone or co-injected. Plasmids were electrotrans-
ferred into tibialis anterior mouse muscle and quantifica-
tion of bioluminescence was performed by ex vivo
measurement with a luminometer as well as non-invasive
in vivo imaging with a CCD camera.
Our data demonstrate that the FGF-1 IRES is as efficient as
the EMCV IRES, with a more stable activity, for long term
expression of bicistronic plasmids in mouse muscle, while
the FGF-2 IRES is very weak. Surprisingly, expression of
monocistronic plasmids expressing LucR of LucF is differ-
ent when they are injected alone or together, and in both
cases the decrease of expression is more drastic than with
the bicistronic plasmid bearing the FGF-1 IRES. This vali-
dates the use of bicistronic vectors to optimize the control
of long term gene co-expression. The FGF-1 IRES is thus a
very attractive molecular tool to co-express molecules of
interest for gene therapy. In addition, we demonstrate that
in vivo imaging with a CCD camera is quantitative and a
more reproducible measurement of transgene expression
than ex vivo measurement, which requires animal sacrifice
during the experiment.
Results
Time course of luciferase expression from IRES-containing 
bicistronic vectors after electrotransfer into mouse tibialis 
anterior muscle
The "Lucky Luke" bicistronic vectors used in this study
contain IRESs of different origins (EMCV, FGF-1 or FGF-
2) located between the LucR and LucF cistrons (Fig. 1A).
The bicistronic mRNAs express LucR in a cap-dependent
manner and LucF by an IRES-dependent mechanism.
Thus, both LucR and LucF are expressed from a singleBMC Biotechnology 2007, 7:74 http://www.biomedcentral.com/1472-6750/7/74
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Quantification of LucR and LucF activities in tibialis anterior muscle from C57BL/6J mice after bicistronic vector electrotrans- fer. Comparison between IRESs from EMCV, FGF-1A and FGF-2 Figure 1
Quantification of LucR and LucF activities in tibialis anterior muscle from C57BL/6J mice after bicistronic vec-
tor electrotransfer. Comparison between IRESs from EMCV, FGF-1A and FGF-2. A. Schematics of bicistronic 
expression vectors used to produce LucR and LucF/F+. The bicistronic cassette, transcriptionally regulated by the 
cytomegalovirus (CMV) promoter, encodes LucR in the first cistron (cap-dependent translation) and LucF (Fig. 1, 2) or LucF+ 
(Fig. 3, 4, 5) in the second cistron (IRES-dependent translation) [28, 36]. B. Bioluminescent signal quantification. Tibialis 
anterior muscle was taken from mice 5, 15 or 30 days after electrotransfer. LucR and LucF activities were measured from mus-
cle extracts using a luminometer. LucR and LucF activities were expressed in Relative Luminescent Units per milligram of 
grinded muscle (RLU/mg) (see Mat. & Meth). Each value corresponds to an individual mouse from an experimental group (n = 
5). C. Mean of bioluminescent signal quantification. Mean values of the LucR (top) and LucF (bottom) activities have 
been represented for each experimental group presented in Fig. 1B (RLU per mg of muscle ± sem, n = 6). D. IRES activity. It 
was obtained from the values shown in fig. 1B, using the following formula: LucF × 1000/LucR. For each time point, the median 
value was noted with a "-". No IRES activity could be calculated in the absence of detectable LucR activity.
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mRNA and IRES activity can be estimated by measuring
the ratio of LucF to LucR.
"Lucky Luke" vectors were electrotransferred into the tibi-
alis anterior muscle of C57BL/6J mice. At the specified
time points following electrotransfer, groups of five mice
(one group for each IRES) were sacrificed and their tibialis
anterior muscles were removed. LucR and LucF activities
were quantified using a luminometer and normalised per
milligram of muscle (Fig. 1B and 1C).
All three vectors showed an overall decline in LucR expres-
sion over time, suggesting that the vector expression is not
stable (Fig. 1C). LucR activities had the same order of
magnitude at day 5, between 0.5 and 6.5 × 106 RLU/mg of
muscle depending upon individual mouse variations (Fig.
1B). This consistency persisted through day 15, however
we observed a significant difference at day 30, where LucR
expression was one order of magnitude superior for the
FGF-2 vector (Fig. 1C). While the experiment was
intended to be conducted over a period of 60 days (data
not shown), very few animals produced significant LucR
activity after day 30.
The IRES regulated expression of the second cistron,
encoding LucF, followed the same slope as the LucR first
cistron, for the three vectors (Fig. 1C). IRES activities (as
measured by the ratio of LucF/LucR), remained stable
until day 15 (Fig. 1D). EMCV IRES activity is very heterog-
enous compared to the activities obtained with the FGF-1
or FGF-2 IRESs. While the EMCV and FGF-1 IRESs showed
activities within the same order of magnitude, the FGF-2
IRES activity was 10 to 20 fold lower. The kinetics could
not be followed after day 30 as the expression level of
LucF became undetectable.
These data show that bicistronic vectors allow expression
of two transgenes with a stable ratio, depending on the
IRES activity which does not change in long term versus
short term vector expression. The FGF-2 IRES activity was
very low in vivo, compared to that of EMCV or FGF-1 IRES.
The FGF-2 IRES containing vector, which expressed less
LucF, appeared to be more stably expressed with respect to
the vectors containing EMCV or FGF-1 IRES.
IRES activities are independent of transgene expression 
levels
Linear regression analysis is another way to estimate the
putative effect of transgene expression levels on IRES
activity and LucF/LucR ratio. Since gene transfer efficiency
is different for each mouse examined (LuR activity reflect-
ing transgene expression), the correlation between LucF
and LucR activities at day 5 were evaluated for each mouse
individually. A plot of LucF activity versus LucR activity is
shown in Fig. 2. At day 5, linear regression analysis
revealed an excellent correlation between LucF and LucR
activities when measured in the same mouse (R2 = 0.9904
for EMCV, R2 = 0.984 for FGF-2, R2 = 0.955 for FGF-1).
These results underline the fact that LucF and LucR are
produced by the same mRNA, with a constant ratio. The
straight line slopes are proportional to the IRES activities
(0.111 for EMCV, 0.081 for FGF-1 and 0.004 for FGF-2
IRES, respectively).
Expression of LucF+ in mice tibialis anterior muscles 
detected by CCD camera imaging
An important problem encountered in the previous exper-
iments is the impossibility to follow IRES activity in a
given individual mouse. This incited us to develop in vivo
imaging methods to follow luciferase expression on live
animals. Quantification of luciferase expression in vivo by
bioluminescence imaging was performed using a CCD
camera, which measures photon emission in live animals.
The vectors described in Figure 1 were assayed for LucF
activity using the CCD camera, but as this technique is less
sensitive than the luminometer, LucF activity was difficult
to detect (data not shown). Thus we replaced LucF by
LucF+ (a stabilised form of LucF) in all bicistronic vectors,
resulting in an approximate 10-fold increase in LucF activ-
ity (data not shown).
LucF versus LucR quantification in tibialis anterior muscles of  C57BL/6J mice at day 5 after electrotransfer Figure 2
LucF versus LucR quantification in tibialis anterior 
muscles of C57BL/6J mice at day 5 after electrotrans-
fer. For each IRES, LucF activity is expressed versus LucR 
activity to assess the correlation between the two activities. 
Linear regressions are shown with the regression coefficient 
R2. The slopes of the regression straight lines are propor-
tional to IRES activities at day 5.
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Bioluminescent images displayed as a pseudocolor image
overlaid on a grey scale reference image of the mouse
muscle revealed an intense signal arising from the muscle
(Fig. 3A). A non-electrotransferred muscle is indicated
with a star (EMCV panel). A scale of pseudocolor is shown
on the lower right side of the image panel. The integration
times required to quantify LucF+ signals varied from 1.7
to 30 minutes (Fig. 3B). In correlation with the data of Fig.
1, the bioluminescence intensity from the muscles
decreased as a function of time. EMCV and FGF-1 muscles
revealed a high bioluminescent mean signal at day 5 (265
and 207 mean grey level/s/ROI respectively), which fol-
lowed similarly decreasing kinetics until day 45 (0.03 and
0.01 mean grey level/s/ROI respectively). As in Fig. 1,
muscles expressing the FGF-2 IRES containing vector
showed a weaker signal at the beginning (3,32 mean grey
level/s/ROI respectively) but, after decrease, showed a sta-
bilisation between day 30 and day 45 (0,02 mean grey
level/s/ROI).
FGF-1 and FGF-2 IRESs provide a more stable LucF+/LucR 
ratio than EMCV IRES in long term expression
To check the correlation between the data obtained with
CCD imaging and that obtained with the luminometer,
analysis of LucR and LucF+ activities were performed ex
vivo using the luminometer at day 5 and at day 55 (Fig. 4).
At day 55, both LucR and LucF+ activities were about 104
times inferior to that observed at day 5 (Fig. 4A). This
decrease correlated well with the data obtained at day 45
with the CCD camera. The LucF+/LucR ratios were not sig-
nificantly different for the FGF-1 and FGF-2 IRESs at day 5
or 55, indicating that the activities of these cellular IRESs
remain constant during long term expression (Fig. 4B). In
contrast, the EMCV IRES activity significantly increased at
day 55.
Altogether these data show that the use of FGF-1 and FGF-
2 IRESs in expression vectors allows to maintain the ratio
of two gene products independently of the vector expres-
sion level and of the time after gene transfer. In contrast,
the EMCV IRES activity is less stable. This study validates
the FGF-1 IRES as an efficient IRES that can be used for
gene transfer in muscle.
Long term expression of transgenes is improved with 
bicistronic compared to monocistronic vectors
It has often been claimed that monocistronic vectors are
expressed with a higher efficiency than bicistronic vectors.
Indeed, a previous report has shown efficient transgene
co-expression seven days after plasmid co-injection [29].
In order to determine if there is an advantage in using
bicistronic vectors rather than mixed monocistronic vec-
tors for long term expression, plasmids encoding either
LucR or LucF were electrotransferred separately or mixed,
and their expression was compared to that of the bicis-
tronic vector bearing the FGF-1 IRES. The time course was
followed up to 21 days (Fig. 5). Luciferase activities were
either monitored by CCD camera imaging (Fig. 5A and
5B) or quantified with the luminometer (Fig. 5C and 5D).
Both analyses showed that the bicistronic vector expres-
sion was lower than that of monocistronic vectors at day
5, except for the monocistronic expressing LucR alone
(Fig. 5A, 5B, 5C). However this difference disappeared at
Visualisation of LucF+ in mice after bicistronic vector elec- trotransfer in tibialis anterior muscle of C57BL/6J mice and  intraperitoneal injection of D-luciferin Figure 3
Visualisation of LucF+ in mice after bicistronic vector 
electrotransfer in tibialis anterior muscle of C57BL/
6J mice and intraperitoneal injection of D-luciferin. 
A. Imaging of bioluminescent signal detected with a 
CCD camera. LucF+ activity was measured in mice electro-
transferred with bicistronic luciferase vectors (expression of 
LucF+ is under the translational control of EMCV, FGF-2 or 
FGF-1A IRES). Images are shown in pseudocolors. Time of 
exposure for each image and a pseudocolor scale are repre-
sented. *: non electrotransferred muscle. B. Mean of biolu-
minescent signal quantification. Signal quantification was 
expressed in mean grey level/sec/ROI* (± sem). For each 
time point, n = 8 for EMCV, n = 10 for FGF-2 and n = 8 for 
FGF-1A. * Region Of Interest, corresponds to the biolumi-
nescent area of the electrotransferred muscle.
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Quantification of LucR and LucF+ activities in mouse muscle 5 and 55 days after electrotransfer Figure 4
Quantification of LucR and LucF+ activities in mouse muscle 5 and 55 days after electrotransfer. LucR and LucF+ 
activities were measured at days 5 and 55 with a luminometer. A. Bioluminescent signal quantification. LucR and LucF+ 
are expressed in RLU/µg total protein. Each value corresponds to one muscle. B. Mean of IRES activities. It was deter-
mined as the ratio of LucF+/LucR multiplied by 100 (± sem, n = 6). Statistical anaysis, p = 0.0022 for EMCV, p = 1 for FGF1A 
and p = 0,0931 for FGF2.
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day 15 and was inverted at day 21: luminometer quantifi-
cations indicated that, for both LucR and LucF, the bicis-
tronic vector was more efficiently expressed, at day 21,
than the monocistronic vectors injected separately or
together. In addition, the relative decrease presented in
Fig. 5B and 5D histograms shows that monocistronic vec-
tor expression decreased more quickly when co-injected
than injected alone.
As regards the LucF to LucR ratio, it was not significantly
modified with the bicistronic vector, whereas LucF expres-
sion decreased more drastically than LucR with the mono-
cistronic vectors. In addition, LucR expression level was
radically weaker for the monocistronic vector single injec-
tion than for co-injection.
These data clearly show that the monocistronic vectors,
although providing a higher expression at day 5, are less
efficient than the bicistronic vector for a long term expres-
sion. In addition, the difference observed for the monocis-
tronic vector injected alone or co-injected renders its
expression unpredictable, in contrast to the bicistronic
vector containing the FGF-1 IRES that provides a stable
transgene ratio in long term expression.
Discussion
In this study, we have analyzed the in vivo expression of
bicistronic and monocistronic vectors following naked
DNA electrotransfer in tibialis anterior mouse muscle. In
particular, we have compared the activities of two cellular
IRESs, FGF-1 and FGF-2 IRESs, to that of the widely used
EMCV IRES. Our data indicate that although vector
expression drastically decreases after 55 days, FGF-1 and
FGF-2 IRESs maintain a constant ratio of the levels of
expression of the two genes encoded by the vector inde-
pendently of the expression level and of the time after
gene transfer. In contrast, the EMCV IRES activity signifi-
cantly increases during the time course. Strikingly, mono-
cistronic vectors, although more efficiently expressed in
short term, showed a long term expression lower than that
of the bicistronic vector containing the FGF-1 IRES. Fur-
thermore, expression of the monocistronic plasmids was
different when injected alone or together and the trans-
gene ratio unstable. These data demonstrate the advan-
tages of IRES-containing bicistronic vectors, and
particularly of the recently identified FGF-1 IRES, as bio-
technological tools for long term co-expression of trans-
genes in skeletal muscle. This study also shows that the
CCD camera is a powerful tool to follow vector expression
and IRES-dependent translation in live animals.
Vector expression is maximal, for monocistronic as well as
bicistronic plasmids, 5 days after electrotransfer. Luci-
ferase activities are however rapidly decreasing. This is sur-
prising as previous reports demonstrate a persistence of
LucF expression until 19 months [12,30]. Bloquet et al
also describe a long-lasting expression of luciferase, which
reached a peak value at 7 days after electrotransfer and a
plateau value that persisted for at least 270 days [12,31].
However, the strong decrease of luciferase expression
observed in our study corresponds to the observation of
Durieux et al who have demonstrated that the duration of
plasmid expression is highly dependent on the promoter
origin. These authors observe a decrease of luciferase
activity of 96% at day 21 compared to day 5 with the CMV
promoter, whereas the decrease is only 19% with the cyto-
chrome c promoter [32]. In our study, we show that the
monocistronic vector expression more drastically
decreases than that of bicistronic vectors. At day 5 the
bicistronic vector is about ten times less expressed than
the co-injected monocistronic vectors, whereas at day 21
the bicistronic vector is significantly more efficiently
expressed than the two monocistronic ones. A possible
mechanism to explain this difference may be that the
stronger expression of the monocistronic vectors may
favor their elimination by the immune system. We can
thus hypothesize, consistent with the Durieux et al study,
that the duration of plasmid expression could be related
to its level of expression. Consequently the strategy of
using plasmid vector with a moderate expression seems
interesting for long term transgene expression. Multicis-
tronic vectors thus offer the possibility to express moder-
ate amounts of several molecules of interest that can have
synergistic effects, rather than huge amounts of a single
molecule which can generate unwished effects.
An important point discovered by the present study is that
IRESs can provide a constant ratio of transgene expres-
sion. At day 5, our linear regression analyses revealed
excellent correlations between LucR and LucF for all three
IRESs, demonstrating that the in vivo IRES activity is not
influenced by the level of transgene expression, which var-
ies between the individual mice (Fig 2). FGF-1 and FGF-2
IRES activities are not significantly modified up to 55 days
after DNA electrotransfer, whereas EMCV IRES activity
slightly increases with time. In contrast, co-injection of
two monocistronic vectors shows drastic variations of the
transgene ratio. This can probably be explained by a pos-
sible competition between the two vectors that could lead
to quicker elimination of one of them if the encoded pro-
tein is more antigenic or has some toxical effect. A previ-
ous report has shown that co-injection of two
monocistronic vectors allows a high degree of co-expres-
sion in muscle after seven days [29]. Here we demonstrate
that bicistronic vectors with IRESs, especially FGF-1 and
FGF-2 IRESs, provide an advantage over co-injected
monocistronic vectors for long term co-expression of
transgenes.BMC Biotechnology 2007, 7:74 http://www.biomedcentral.com/1472-6750/7/74
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Comparison of LucR and LucF+ monocistronic versus bicistronic vector expression after electrotransfer in mouse muscle Figure 5
Comparison of LucR and LucF+ monocistronic versus bicistronic vector expression after electrotransfer in 
mouse muscle. Mice were electrotransferred with either 30 µg of monocistronic plasmid encoding LucR or LucF+ (Mono 
LucR or Mono LucF, respectively), or with a mixture (30 µg + 30 µg) of the two plasmids (Mono LucR + LucF), or with 30 µg 
of the bicistronic plasmid containing the FGF-1 IRES (IRES FGF1A). LucR and LucF+ activities were measured from 5 to 21 days 
after electrotransfer. A. Detection of the LucF+ signal with the CCD camera. LucF+ activity was detected at days 5, 15 
and 21 in live animals as in Figure 3. Images are shown in pseudocolors. Time of exposure and a pseudocolor scale are repre-
sented. B. LucF+ signal quantification. On the top panel, the values detected with the CCD camera for each time point are 
expressed in mean grey level/second/ROI (mean ± sem, n = 6). The bottom panel shows the LucF+ relative quantification at 
day 5 (D5), day 15 (D15) and day 21 (D21) for each vector. C. Luciferase activities quantification at day 5 and 21 after 
electrotransfer. Two groups of mice were sacrificed at day 5 and 21, and muscles lysates were used for luciferase activity 
quantification using the luminometer. LucR (top panel) and LucF+ (bottom panel) are expressed in RLU/µg total proteins 
(mean ± sem, n = 6). D. Bioluminescent signal relative quantification. Luciferase relative quantification was obtained for 
each vector at day 5 (D5) and day 21 (D21).
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The CCD camera appears as a precious tool to follow the
kinetics of LucF activity, but proved problematic with
respect to LucR monitoring, which was hindered due to
substrate precipitation and CCD camera sensitivity (not
shown). This camera allowed us to detect and quantify
muscle bioluminescence from the same mouse over a
time course. The use of the CCD camera reduces the
number of sacrificed animals per experiment, sometimes
by as much as one order of magnitude, because it allows
the comprehensive assessment of each animal over the
entire duration of the process under investigation [33].
Furthermore, the LucF+ activities observed with the three
IRESs exactly correlate with those observed with the lumi-
nometer, indicating that the camera quantitatively reflects
LucF+ expression (not shown). However, sensitivity is
inferior with the camera compared to the luminometer, as
previously reported (Fig. 5 and 6) [34].
Finally, one may find it unclear how would this translate
into a meaningful gene therapy, as detection of luciferase
is very sensitive and the signal amplified. Of course, detec-
tion based on enzymatic activity does not mean that the
amount of protein produced would be biologically mean-
ingful in all cases. However, expression of luciferase in
bicistronic vectors is very useful in preclinical assays for
gene therapy as it allows to monitor the expression of the
gene of interest on live animals. Furthermore, in various
gene therapy applications such as cancer or lower limb
ischemia, gene therapy approaches may use secreted mol-
ecules (angiogenic or anti-angiogenic factors) that are
active in very low amounts. In such cases it is not neces-
sary to flood the organism with therapeutic molecules but
more interesting to obtain long term expression of mod-
erate amounts of several therapeutic molecules having
synergistic effects. Bi- or multicistronic vectors are thus
particularly attractive to co-express combinations of such
therapeutic molecules.
Conclusion
In conclusion, our data show that bioluminescence imag-
ing in vivo offers a powerful tool for the quantitative real
time analysis of gene expression [27,35]. We validate the
advantage of using IRES-containing bicistronic vectors,
rather than monocistronic vectors, for long term expres-
sion of transgenes and show that one can deduce the
expression of the first cistron by monitoring the expres-
sion of an IRES-driven second reporter cistron in vivo. This
can be applied to monitor the expression of a gene of
interest.
Our results reveal the FGF-1 cellular IRES as an interesting
new tool to be used in multicistronic vectors for three rea-
sons. It is of cellular origin, an important aspect with
respect to the goal of removing viral sequences from trans-
genic vectors. It is shorter and more flexible, thus easier to
use for cloning genes of interest than the EMCV IRES.
Finally it is equally efficient as the EMCV IRES in terms of
expression kinetics in muscle and its activity is more stable
when driving transgene long term expression. Together
the data presented here will enable the construction of
new expression cassettes that express combinations of
molecules for therapeutic purposes.
Methods
Recombinant vectors
All bicistronic vectors contain the expression cassette
"Renilla  Luciferase (LucR) – IRES – Firefly Luciferase
(LucF)" under the control of the cytomegalovirus (CMV)
promoter with the SV40 polyA signal. The IRES sequence
is of viral (EMCV) or cellular origin (FGF-2 or FGF-1). A
chimeric intron of human β-globin origin is present
between the CMV promoter and the expression cassette
[36]. LucR was subcloned from pRL-CMV, LucF from
pGL2 and LucF+ from pGL3 (Promega, France). The plas-
mids used for the study of EMCV, FGF-1 or FGF-2 IRES
were pCREL, pCRF1AL and pCRFL respectively [17,28].
The monocistronic plasmids CMV-LucR and CMV-LucF+
had the same vector skeleton as the bicistronic vectors.
The plasmids used for injection in mice were purified with
a MAXI EndoFree plasmid purification kit (QIAGEN). For
ex vivo bioluminescence quantification, bicistronic vectors
contained LucF. For in vivo bioluminescent imaging, LucF
was replaced by LucF+ because of its higher stability.
Mice
6-week old female C57BL/6J@Rj were purchased from
Janvier laboratories. They were housed in the animal facil-
ity of the IFR31 (Toulouse, France) and cared for in con-
formity with the guidelines of the INSERM Ethics
Committee. Mice were anesthetized by intraperitoneal
injection of Ketamine (125 mg/kg Body Weight) and
Xylazine (10 mg/kg Body Weight) solutions and mice legs
were depilated using a depilation cream (Veet).
In vivo tibialis anterior muscle electrotransfer
Groups of 5 mice received an intramuscular injection with
naked DNA in saline solution followed by electrotransfer.
30 to 45 µg of bicistronic vector (in a 30 µl final volume)
was injected intramuscularly using an Insulin syringe
(300 U, Myjector u-100 insulin, Terumo). A conducting
gel was applied on both sides of the injected muscle (Eko
gel, Asept. InMed S.A.). The electric pulses were delivered
using a generator (ECM 830, BTX) and Tweezerhode elec-
trodes (522, 10 mm diameter, BTX) placed on both sides
of the tibialis anterior muscle. Eight 20 ms pulses were
applied with a voltage setting of 200 V/cm at a frequency
of 2 Hz. One muscle, which did not receive any DNA
injection, was included as a control.BMC Biotechnology 2007, 7:74 http://www.biomedcentral.com/1472-6750/7/74
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Quantification of LucF and LucR expression in tibialis 
anterior muscle lysate with a luminometer
At time points between 5 and 60 days after electrotransfer,
mice were anesthetized and tibialis anterior muscles were
removed and stored at -80°C. Lysates were generated by
grinding the tissue in Passive Lysis Buffer (Promega,
France) using an Ultra-Turrax T25 (Janke and Kunkel,
IKAR Labortechnik). Quantification of ex vivo biolumines-
cence was performed with a luminometer (Centro LB960,
Berthold) using the Dual-Luciferase®  Reporter Assay
(Promega, France) according to the manufacturer's
instructions.
Raw data were obtained from the MicroWin 2000 soft-
ware. The mean control value (corresponding to non elec-
trotransferred muscle) was multiplied by 2 and subtracted
from each sample value. Results were then expressed
either in Relative Luminescent Unit (RLU)/mg of muscle
weight or in RLU/µg of total protein.
Quantification of total protein with Dc Protein Assay
The amount of total protein in the ground muscle was
quantitated using the Dc Protein Assay (Bio-Rad). Briefly,
20 µl of S reagent was mixed with 1 mL of A reagent to
obtain the A' reagent. 25 µl of this A' mix was added to 1
µl of the sample in a 96 well plate (Nunclon TM) and 200
µl of B reagent was added. After 10 minutes incubation
time, the OD was read at 690 nm. In parallel, a BSA range
standard was used to correlate the OD with the total pro-
tein amount in the sample.
In vivo bioluminescence imaging and quantification
In vivo bioluminescence imaging was conducted using a
cooled CCD camera (cooled to -80°C) mounted on a dark
box chamber with a camera controller, a camera cooling
system and a computer system for data acquisition and
analysis (deep cooling BTW 512 S/N, camera 1394 ORCA
II, Hamamatsu Photonics). 5 days after electrotransfer
(and up to 30 days or 55 days), mice were anesthetized
and mice legs were depilated. D-luciferin was then
injected intraperitoneously (50 mg/kg body weight, Luci-
ferin-EF™, Promega France) and after 5 min incubation
time mice were placed in the dark box chamber. During
image acquisition animal body temperature was regulated
using a heating plate integrated within the dark box cham-
ber. A grey scale body surface image was collected in the
chamber under dim illumination, followed by acquisition
and overlap of the pseudocolor image representing the
spatial distribution of detected photon counts emerging
from active luciferase within the animal. An integration
time of 1.6 to 30 min was used for luminescent image
acquisition. The grey scale images and bioluminescence
color images were superimposed using the Simple PCI
software (Hamamatsu Photonics). Signal intensity was
quantified as the mean of grey level per second of time
exposure within a region of interest (ROI) prescribed over
the muscle using the Simple PCI software. Levels of lumi-
nescence are indicated by pseudocolors on a scale of 0 to
255 units. The control ROI chosen on the abdomen per-
mitted measurement of the background, which is sub-
tracted from the sample values.
Statistical analysis
Statistical analysis was performed using the program
Prism® (GraphPad Software Inc.). Mann Whitney tests
(two-tailed) were achieved to compare IRES activities at
day 5 and day 55 after gene transfer.
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